Therefore, we aimed to compare the outcomes of therapeutic CGM users (therapeutic and/or nonadjunctive CGM are approved for clinical decision-making without confirmatory SMBG; ie, even if a patient uses both, decisions will be made based on CGM readings) vs prevalent SMBG users in insulin-treated Medicare beneficiaries with coexisting diabetes and ADRD. The gene discussed is INS; the disease is diabetes mellitus.